Adult trials
- SCANALL: Study of Nordic CML and ALL Patients using Next Generation Sequencing Analysis for Low Level Mutations
- EWALL-PH-03: An open label, 3-arm, randomised phase II study to compare the safety and efficacy of ponatinib in combination with either chemotherapy or blinatumomab with imatinib plus chemotherapy as front-line therapy for patients aged 55 years and over with Philadelphia chromosome-positive (Ph+ or BCR-ABL+) acute lymphoblastic leukemia (ALL)
- ALLTogether: A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)
- PONATINIB-3001:A phase 3, randomized, open-label, multicenter study comparing ponatinib versus imatinib, administered in combination with reduced-intensity chemotherapy, in patients with newly diagnosed philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL)
- LOXO-IDH-20001: A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations
- CVOB560A12101: A phase 1b, multicenter study of VOB560 in combination with MIK665 in patients with relapsed/refractory non-hodgkin lymphoma, relapsed/refractory acute myeloid leukemia, or relapsed /refractory multiple myeloma
- CHDM201H12101C: A phase Ib, multi-arm, open-label, study of HDM201 in combination with MBG453 or venetoclax in adult subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
- HO150, AMLSG 29-18: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy
- HO156, AMLSG 28-18: A phase 3, multicenter, open-label, randomized study with gilteritinib or midostaurine in combination with induction and consolidation chemotherapy followed by 1 year of maintenance treatment in patients with newly diagnosed acute myeloid leukaemia (AML) or myelodysplastic syndromes with excess blasts (MDS-EB2) with FLT3 mutations who are eligible for intensive chemotherapy
- ZEST: A randomized phase 3 double-blinded study comparing the efficacy and safety of niraparib to placebo in participants with either triple-negative breast cancer or her2-negative brca-mutated breast cancer with molecular disease based on presence of circulating tumor dna after definitive therapy
- DESTINY: An open-label, multinational, multicenter, phase 3b/4 study of trastuzumab deruxtecan in patients with or without baseline brain metastasis with previously treated advanced/metastatic her2-positive breast cancer (DESTINY-Breast12)
- MO42319 KATE3: A randomized, multicenter, double-blind, placebo-controlled phase III study of the efficacy and safety of trastuzumab emtansine in combination with atezolizumab or placebo in patients with HER2-positive and PD-L1- positive locally advanced or metastatic breast cancer who have received prior trastuzumab- (+/- pertuzumab) and taxane-based therapy (kate3)
- CA209-7FL: A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in the Treatment of High-risk, Stage II-III Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer
- IMPASSION: A phase III, randomized, double-blind, placebo-controlled, multicentre study of the efficacy and safety of atezolizumab plus chemotherapy for patients with early relapsing recurrent (inoperable locally advanced or metastatic) triple-negative breast cancer
- CLL17: A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)
- CJBH492A12101: A phase I/Ib open-label, multi-center dose escalation study of JBH492 in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Non-Hodgkin´s Lymphoma (NHL)
- MK6482-012: An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as Firstline Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (cRCC)
- MK6482-011: An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti PD-1/L1 Therapy
- XHUTCHISON 2018-689-00US1: A phase 1, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hmpl-689 in patients with relapsed or refractory lymphoma
- HMPL-523: A phase I, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hmpl-523 in patients with relapsed or refractory lymphoma
- GCT3013-05: A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
- GCT3013-02: A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma
- GCT3013-01: A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma (GCT3013-01)
- NP30179: A Multicenter, open-label, phase I study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of RO7082859 as a single agent and in combination with obinutuzumab administered after a fixed, single dose pre-treatment of obinutuzumab ( Gazyva/ Gazyvaro ) in patient with relapsed / refractory B-cell Non Hodgin`s Lymphoma
- ENRICH: Randomised, open label study of Rituximab / Ibrutinib vs Rituximab / Chemotherapy in older patients with untreated mantle cell lymphoma
- CJBH492A12101: A phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL)
- JCAR: A phase 2, single-arm, multi-cohort, multi-center trial to determine the efficacy and safety of JCAR017 in adult subjects with aggressive B-cell Non-Hodgkin lymphoma
- LYMRIT: A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma
- POLAR BEAR: R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, >80 years, or fail >75 years - an open label randomized Nordic Lymphoma group. Phase III trial- NLG-LBC7
- EORTC 1612-MG: Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immediate combination of immunotherapy in patients with unresectable or metastatic melanoma with BRAF V600 mutation: an EORTC randomized phase II study (EBIN)
- CA022-001: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors
- CA030-001: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors
- INCB 50465-313: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants with Myelofibrosis
- INCB 50465-304: A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
- INCB 57643-103: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants with Myelofibrosis
- COBRA: A randomized, open-label phase 3 study of carfilzomib, lenalidomide, and dexamethasone versus bortezomib, lenalidomide and dexamethasone (krd vs. Vrd) in patients with newly diagnosed multiple myeloma
- CC-92480-MM-001: A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma
- TALAPRO-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
- TALAPRO-3: A Phase 3, Randomized, double-blind, Study of Talazoparib with Enzalutamide versus Placebo with Enzalutamide in men with DDR Gene mutated metastatic Castration-Sensitive Prostate Cancer
- ESTO-2: Impact of Atorvastatin on Prostate Cancer Progression During ADT
- SPCG17: Prostate Cancer Active Surveillance Trigger Trial (PCASTT)
- BAYER20511: Open-label, Non-randomized Phase 1, Multicenter Study to Assess Radium- 223 Biodistribution in Participants With Bone Metastatic Castration Resistant Prostate Cancer (CRPC) Receiving Radium-223 Dichloride Treatment
- CYPIDES: Safety and pharmacokinetics of ODM-208 in patients with metastatic castration-resistant prostate cancer
- HERO: Randomized, open-label, parallel group efficacy and safety study to evaluate oral daily relugolix 120 mg to Leuprolide in patients with androgen-sensitive advanced prostate
- THORIUM PSMA: A Phase 1, open label, first in human, multi center, study to evaluate the safety, tolerability, pharmacokinetics and anti tumor activity of a thorium-227 labeled antibody-chelator conjugate BAY 2315497 injection, in patient with metastatic castration resistent prostate cancer
- ProScreen: A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer
- PRIAS: Prostate cancer Research International: Active Surveillance - guideline and study for the expectant management of localized prostate cancer with curative intent
- SPCG-15: Primary Radical Prostatectomy Versus Primary Radiotherapy for Locally Advanced Prostate Cancer: an Open Randomized Clinical Trial
- RAMPP: Multicentric, Prospective, Randomized Controlled Trial Comparing Best Systemic Therapy (BST) With Radical Prostatectomy or BST Alone in the Management of Men With Pauci-metastatic Prostate Cancer
- INCB 099318-122: A phase 1 study exploring the safety, tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in participants with select advanced solid tumors
- FINPROVE: The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile
- TILT: A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Patients with Injectable Solid Tumors
- MATINS: A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients
Pediatric trials
- LELU-study: Skeletal complications in childhood leukemia - tissue-level mechanisms
- ITCC-059: A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric Cd22 positive relapsed ALL
- CASSIOPEIA: A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
- EsPhALL2017/COGAALL1631: International phase III trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
- (SIOP CNS GCT II): Prospective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors (SIOPCNSGCTII)
- SIOP EPENDYMOMA: An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma (SIOP-EP-II)
- (SIOP) PNET 5 Medulloblastooma: An international prospective study on clinically standard-risk Medulloblastoma in children older than 3 to 5 years with low-risk biological profile (PNET 5 MB - LR) or average-risk biological profile (PNET 5 MB -SR), SIOP PNET 5 Medulloblastoma
- EuroNet-PHL C2 (opening soon) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
- LBL 2018: International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma (LBL 2018)
- B-NHL 2013 2.2: Treatment protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (B-NHL 2013)
- IntreALL SR 2010: International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010
- IntreALL HR 2010: International Study for Treatment of High Risk Childhood Relapsed ALL 2010
- rEECur
- BAY27257556 (will be opening in autumn 2021): PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib
- INFORM: INdividualized Therapy FOr Relapsed Malignancies in Childhood
- iCAN-PEDI
- SIOP Umbrella 2016 (will be opening)
- PHITT: Paediatric Hepatic International Tumour Trial (PHITT)
- High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2) (will be opening)
HUS Helsinki University Central Hospital, Comprehensive Cancer Center: haluantutkimuspotilaaksi@hus.fi
HUS Helsinki University Hospital, New Chidren’s Hospital: Clinical Trial Unit (CTU) of the new Children´s Hospital
Participation in medical research
In accordance with Finnish treatment practice, we need a referral from the attending physician to participate in the study. We also get the necessary information about the suitability for the study from the attending physician.
